LaBrosse Nicole's Form 4 filing
Halozyme Therapeutics, Inc. (HALO) · filed Jul 23, 2024
- Accession no.
- 0001415889-24-019936
- Filed
- Jul 23, 2024
- Trade date
- Jul 22, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $269.6K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| LaBrosse NicoleCIK 0001910662 | Officer (SVP, CHIEF FINANCIAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 22, 2024 | Common Stock | MOption exerciseAcquired | +4,008 | $22.50 | +$90,180 | 19,488 | Direct | |
| Jul 22, 2024 | Common Stock | SSaleDisposed | −4,008 | $53.85 | −$215,830.8 | 15,480 | Direct | |
| Jul 22, 2024 | Common Stock | MOption exerciseAcquired | +992 | $22.50 | +$22,320 | 16,472 | Direct | |
| Jul 22, 2024 | Common Stock | SSaleDisposed | −992 | $54.25 | −$53,816 | 15,480 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 22, 2024 | Common Stock | MOption exerciseDisposed | −5,000 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.